Study on risk factors, bacterial species, and drug resistance of acute pyelonephritis associated with ureteral stent after percutaneous nephrolithotomy

Guo Jiang 1 · Jiang Li 1 · He Long 2 · Chen Qiulin 2 · Ren Jin 2 · Yang Yaodong 2 · Dong Xingyou 2 · Zhao Jiang 2 · Zhang Zhenyang 2

Received: 7 January 2020 / Accepted: 24 September 2020 / Published online: 9 October 2020
© The Author(s) 2020

Abstract
The purpose of this study is to explore the risk factors, bacterial species, and drug resistance of acute pyelonephritis (AP) associated with ureteral stent after percutaneous nephrolithotomy (PCNL) and to provide reference for clinical intervention. The clinical data of 415 patients with indwelling ureteral stent after PCNL from December 2016 to May 2019 were analyzed retrospectively. The patients were divided into infection group (n = 54) and non-infection group (n = 361) according to whether patients had AP. Patients’ clinical data, blood and urine bacterial culture, and drug sensitivity were collected and analyzed. The incidence of AP associated with ureteral stent after PCNL was 13.01% and diabetes mellitus (P = 0.001), postoperative stone residue (P = 0.002), urinary leucocytes ≥ 100/HP (P = 0.018), positive urine culture results (P = 0.001), ureteral stent retention time ≥ 8 weeks (P = 0.004), and high S.T.O.N.E. score (P = 0.014) are independent risk factors for it. Escherichia coli (40.54%, 47.82%), Klebsiella pneumoniae (16.21%, 15.21%), Pseudomonas aeruginosa (10.81%, 4.34%), Enterococcus faecalis (21.6%, 19.56%), and epidermis Staphylococci (10.81%, 13.33%) are the main pathogens in blood and urine. The main sensitive drugs of pathogenic bacteria are imipenem, meropenem, tigecycline, piperacillin/tazobactam, ceftazidime, linezolid, teicoplanin, levofloxacin, norfloxacin, penicillin G, first, and second-generation cephalosporins showed a strong drug resistance rate (> 70%). This study found that diabetes, postoperative stone residuals, urinary leukocytes ≥ 100 cells/HP, positive urine culture results, ureteral stent indwelling time ≥ 8 weeks, and high S.T.O.N.E. score were independent of AP associated with ureteral stent after PCNL risk factors and Escherichia coli is the main pathogenic bacteria and shows drug resistance.

Keywords Percutaneous nephrolithotomy · Ureteral stent · Acute pyelonephritis · Infection · Bacterial strain · Drug sensitivity · Drug resistance

Introduction
Kidney stones are a common and frequently occurring disease of the urinary system. The incidence is 10.34% in men and 6.62% in women [1]. Percutaneous nephrolithotomy (PCNL) is the main treatment method for kidney stones [2, 3]. PCNL has been used as an important minimally invasive method for the treatment of kidney stones because of its small trauma and rapid recovery [2, 3]. Indwelling double J-tube after PCNL can provide advantages such as urinary tract obstruction, drainage of urine, and protection of renal function [4, 5]. But after PCNL operation, the ureteral stent can cause the patient’s waist and abdomen discomfort, bladder irritation, hematuria, stent tube displacement, and other adverse events, especially urinary tract infection is one of the more common complications [4, 5]. There are some data suggesting an association between indwelling ureteral stents and urinary tract infections, including a recent prospectively performed study reporting an 11% incidence of UTIs in stented patients [4, 5]. In clinic, antibiotics are mainly used to treat acute pyelonephritis (AP) associated with ureteral stent after PCNL. However, clinical
observations have shown that this infection is not effectively treated with ordinary second-generation cephalosporins and quinolone antibacterials such as levofloxacin, which indicates that the pathogenic bacteria of this kind of infection are drug resistance and difficult to treat. Accordingly, this study retrospectively analyzed the clinical data of 415 patients with indwelling ureteral stent after PCNL treatment in our hospital from December 2016 to May 2019 to explore the risk factors, bacterial strains, and drug susceptibility of AP associated with ureteral stent after PCNL, and provide a reference for clinical intervention.

**Materials and methods**

**Case collection and establishment of diagnostic criteria for AP**

From December 2016 to May 2019, 415 cases of PCNL patients with ureteral stent (retention time ≥ 4 weeks) were collected. According to whether the patients had AP, they were divided into infection group (n = 54) and non-infection group (n = 361). Inclusion criteria: (1) first diagnosis of kidney stones by abdominal ultrasound, CT, or intravenous pyelography; (2) first kidney stones undergoing PCNL and indwelling ureteral stent; (3) patients and family members agreed with the study and signed informed consent. Exclusion criteria: (1) patients with contraindications for renal calculi operation; (2) patients with severe cardiopulmonary dysfunction; (3) patients with immune system disease; (4) patients with blood system disease; (5) patients with severe liver and kidney dysfunction; (6) patients with previous history of renal calculi operation; (7) patients with pyonephrosis; (8) patients with other organ infection and febrile diseases. Diagnostic criteria of AP: (1) the patient has acute pain in one or both sides of the back (the pain can radiate to the waist, abdomen, and/or groin area); (2) percussion pain or tenderness of costal ridge angle; (3) body temperature ≥ 38.0 °C; (4) blood routine examination showed that leukocyte was more than 10.0 × 10⁹/L; (5) urine routine white blood cell count > 5/HP and/or middle urine culture positive, and colony count ≥ 10⁵ CFU/mL. It can be diagnosed as AP if it is greater than or equal to the three of the above 5 [6–8]. This study was approved by the Ethics Committee of Anyue People’s Hospital of Ziyang City. All the patients and their families in the study signed the relevant informed consent.

**PCNL operation mode and clinical data collection**

The operation procedure and method of PCNL were performed in accordance with the previous literature standards [9–11]. The data of gender, age, BMI, history of basic diseases, location of affected kidney, S.T.O.N.E. score, operation time, stone residue after operation, urine leukocyte count, ureteral stent retention time, operation channel size, blood, and urine bacterial culture were collected for statistical analysis. The S.T.O.N.E. score of renal calculi refers to the previous report [12, 13].

**Bacterial culture, identification, and drug sensitivity test**

Patients’ blood and mid-section urine were collected for bacterial culture and identification. MicroScan WalkAway 40 bacterial identification instrument from German Siemens Company was used for bacterial strain identification and bacterial culture experiment, and bacterial drug sensitivity test. Bacterial culture, identification, and drug susceptibility experiments were completed with the assistance of the clinical laboratory of our hospital.

**Statistical analysis**

SPSS 19.0 statistical analysis software is used for data analysis. The data of measurement data are expressed in mean ± standard deviation, analyzed by t test; count data is expressed as a percentage (%) and analyzed by χ² test. The factors with statistical significance were analyzed by logistic regression analysis, and the regression coefficient (β), relative risk ratio (or), and 95% confidence interval (95% CI) were calculated. The difference was statistically significant (P < 0.05).

**Results**

**Single factor analysis of risk factors for AP associated with ureteral stent after PCNL**

According to the exclusion and inclusion criteria, a total of 415 patients were included in the study, 54 cases in the infected group and 361 cases in the non-infected group. There were 192 women (46.26%) and 223 men (53.73%). The incidence of AP associated with ureteral stent after PCNL is 13.01%. As shown in Table 1, we found that the risk factors of AP associated with ureteral stent after PCNL were gender, diabetes mellitus, stone residue after operation, white blood cells in urine ≥ 100/HP, retention time of ureteral stent ≥ 8 weeks, positive urine culture result, and high S.T.O.N.E. score (especially the large stone size, severe obstruction, and multiple kidney calices involved). However, age, BMI, location of affected kidney, history of hypertension, history of coronary heart disease, history of chronic renal insufficiency, and size of operation channel...
were not risk factors of AP associated with ureteral stent after PCNL.

**Multiple logistic regression analysis of risk factors of AP associated with ureteral stent after PCNL**

As shown in Table 2, multiple logistic regression analysis showed that diabetes mellitus \( (P = 0.001) \), postoperative stone residue \( (P = 0.002) \), urinary leucocytes \( \geq 100/HP \) \( (P = 0.018) \), positive urine culture results \( (P = 0.001) \), ureteral stent retention time \( \geq 8 \) weeks \( (P = 0.004) \), and high S.T.O.N.E. score \( (P = 0.014, \text{especially the large stone size, severe obstruction, and multiple kidney calices involved}) \) are independent risk factors for AP associated with ureteral stent after PCNL. Among them, diabetes history, postoperative stone residue, positive urine culture results, and ureteral stent retention time \( \geq 8 \) weeks had the highest impact.

**Bacterial culture and drug sensitivity analysis of urine and blood samples of patients with AP associated with ureteral stent after PCNL**

As shown in Table 3, there were 54 blood and urine samples, 37 blood culture positive samples (68.51%), and 45 urine culture positive samples (85.18%). As shown in Table 3, in the culture components of blood and urine bacteria, Gram-
negative bacteria are mainly *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*, and Gram-positive bacteria are mainly *Enterococcus faecalis* and *Staphylococcus epidermidis*. As shown in Table 4, we analyzed the drug resistance of bacteria in the blood and urine of patients and found that the main sensitive drugs for pathogenic bacteria (drug resistance rate < 15%) are imipenem, meropenem, tigecycline, piperacillin/tazobactam, ceftazidime, linezolid, teicoplanin, levofloxacin, tigecycline, etc., but levofloxacin, norfloxacin, penicillin G, compound sinomine, and second-generation cephalosporins showed strong drug resistance (> 70%).

### Discussion

Ureteral stent is the most commonly used medical implant for urological surgery. It is widely used in clinical practice because it can relieve urinary tract obstruction, drain urine, and protect renal function [14, 15]. After PCNL operation, ureteral stent is usually retained for 4–6 weeks, but some patients need to keep ureteral stent for a long time because of the complex condition. During the indwelling of ureteral stent after PCNL, AP associated with ureteral stent is a more common complication, and some severe cases can induce retrograde urogenic sepsis endangering the life of patients [16–18]. Previous studies have suggested that the incidence of bacteriuria and urinary tract infection related to ureteral stent is 11–45% [4, 5]. In this study, we found that the incidence of AP associated with ureteral stent after PCNL was approximately 13.01%. The results are similar to previous reports, suggesting that the incidence of AP associated with ureteral stent after PCNL is higher, and urologists need to pay more attention.

Studies suggest that infections are a more common complication after PCNL. Long operation time, intraoperative bleeding, excessive intrapelvic pressure, and urinary tract obstruction are all risk factors for postoperative infection of PCNL [19–21]. In this study, we found that diabetes mellitus, postoperative stone residue, urinary leucocytes ≥ 100/HP, positive urine culture results, ureteral stent retention time ≥ 8 weeks, and high S.T.O.N.E. score (especially the large stone size, severe obstruction, and multiple kidney calices involved) are independent risk factors for AP associated with ureteral stent after PCNL. The possible reasons for the findings are the following: (1) the immune defense of diabetes patients is reduced, and the blood glucose of some patients is not well controlled for a long time, and the whole body glucose metabolism is disordered, which is conducive to the invasion, production, and reproduction of bacteria. In addition, it is difficult to remove the residual bacteria in diabetic patients before PCNL operation. The ureteral stent is more conducive to the continuous colonization and reproduction of bacteria [22, 23]; (2) as a foreign body, the ureteral stent is accompanied by the friction damage of the ureteral stent to the ureteral mucosa when the human body moves, which destroys the defense mechanism of the urinary tract epithelial system. In

| Specimen | n (54) | *Escherichia coli* | *Enterococcus faecalis* | *Staphylococcus epidermidis* | *Klebsiella pneumoniae* | *Pseudomonas aeruginosa* | Fungus |
|----------|--------|--------------------|-------------------------|------------------------------|------------------------|-------------------------|--------|
| Blood    | 37 (68.51%) | 15 (40.54%) | 8 (21.62%) | 4 (10.81%) | 6 (16.21%) | 4 (10.81%) | 0 (0%) |
| Urine    | 46 (85.18%) | 22 (47.82%) | 9 (19.56%) | 5 (13.33%) | 7 (15.21%) | 2 (4.34%) | 1 (2.17%) |
addition, the long-term retention of the ureteral stent (≥ 8 weeks) can form stone crystals on the surface of the ureteral stent, which is conducive to the adsorption, growth, and reproduction of bacteria [4, 5]; (3) PCNL was positive for urine culture before surgery, and turned negative after active anti-infective treatment. However, for some complex stones with high S.T.O.N.E. scores (especially the large stone size, severe obstruction, and multiple kidney calices involved), residual stones are present after surgery, and bacterial colonies are often present in the residual stones. These bacterial colonies, under the natural protective barrier provided by the bacterial biofilm, prevent the killing of bacteria by antibacterial drugs and eventually lead to bacterial reproduction and infection recurrence [4, 5, 21].

It is suggested that *Escherichia coli*, *Enterococcus*, *Klebsiella pneumoniae*, *Proteus mirabilis*, and *Pseudomonas aeruginosa* are the common pathogens of urinary tract infection induced by urinary stones [24, 25]. In this study, we found that among the pathogens causing AP associated with ureteral stent after PCNL, Gram-negative bacteria were mainly *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*, and Gram-positive bacteria are mainly *Enterococcus faecalis* and *Staphylococcus epidermidis*. In recent years, the unreasonable use or abuse of antibiotics in China, the drug resistance of pathogenic bacteria is becoming more and more serious, especially in patients with kidney stones and urinary tract infection. In China, the resistance rate of *E. coli* to quinolones (levofloxacin) and gentamycin was close to 50%, and the resistance rate to cephalosporins increased gradually, among which 79.2% and 66.5% to the first and second-generation cephalosporins respectively [26–28]. In this study, we also found that the pathogens of AP associated with ureteral stent after PCNL had strong resistance to quinolones (levofloxacin) and the first and second-generation cephalosporins (the resistance rate was more than 50%). These results suggest that quinolones (levofloxacin) and the first and second-generation cephalosporins are no longer suitable for the treatment of AP associated with ureteral stent after PCNL.

### Table 4 Analysis of urine and blood bacterial drug resistance rates of AP associated with double J-tube after PCNL (n = 83, %)

| Drug                          | *Escherichia coli* | *Enterococcus faecalis* | *Staphylococcus epidermidis* | *Klebsiella pneumoniae* | *Pseudomonas aeruginosa* |
|-------------------------------|-------------------|-------------------------|-----------------------------|------------------------|------------------------|
| Penicillin G                  | 100%              | 100%                    | 95.32%                      | 100%                   | 100%                   |
| Ampicillin                    | 93.97%            | 100%                    | 81.92%                      | 100%                   | 93.97%                 |
| Sulfamethoxazole compound     | 86.74%            | 92.77%                  | 85.54%                      | 96.38%                 | 100%                   |
| Cefepime                      | 81.92%            | 85.54%                  | 89.15%                      | 93.97%                 | 95.18%                 |
| Ceftriaxone                   | 72.28%            | 77.10%                  | 71.08%                      | 79.51%                 | 83.13%                 |
| Ciprofloxacin                 | 42.16%            | 36.14%                  | 39.75%                      | 57.83%                 | 50.60%                 |
| Norfloxacin                   | 69.87%            | 71.08%                  | 61.44%                      | 53.01%                 | 63.85%                 |
| Levofloxacin                  | 78.31%            | 74.98%                  | 66.26%                      | 81.92%                 | 85.54%                 |
| Amoxicillin-clavulanic acid   | 37.34%            | 32.53%                  | 31.32%                      | 46.51%                 | 53.01%                 |
| Amikacin                      | 9.63%             | 13.25%                  | 8.43%                       | 12.04%                 | 10.46%                 |
| Piperacillin/tazobactam       | 6.02%             | 7.23%                   | 9.63%                       | 13.08%                 | 14.45%                 |
| Cefoperazone/sulbactam sodium | 15.66%            | 13.25%                  | 18.07%                      | 16.86%                 | 12.04%                 |
| Meropenem                     | 2.40%             | 1.20%                   | 0%                          | 0%                     | 3.61%                  |
| Imipenem                      | 0%                | 0%                      | 0%                          | 0%                     | 0%                     |
| Ceftazidime                   | 23.25%            | 19.27%                  | 21.68%                      | 18.07%                 | 24.09%                 |
| Furantoin                     | 36.14%            | 39.75%                  | 34.93%                      | 48.19%                 | 56.63%                 |
| Linezolid                     | 0%                | 0%                      | 0%                          | 0%                     | 0%                     |
| Teicoplanin                   | 0%                | 0%                      | 0%                          | 0%                     | 0%                     |
| Levofloxacin                  | 0%                | 0%                      | 0%                          | 0%                     | 0%                     |
| Vancomycin                    | 0%                | 0%                      | 0%                          | 0%                     | 2.40%                  |
| Tigecycline                   | 0%                | 0%                      | 0%                          | 0%                     | 0%                     |
(amikacin) are highly sensitive to pathogens and can be used as the first choice of drugs, but aminoglycoside antibiotics (amikacin) should be used carefully due to renal toxicity and ototoxicity. In addition, we also found that the pathogenic bacteria were sensitive to carbapenems (meropenem, imipenem), glycol tetracyclines (tigecycline), azolidone antibiotics (linezolid), glycopeptide antibiotics (teicoplanin, vancomycin), and other drugs, and the resistance rate was less than 10%. Therefore, for severe infections, we recommend the use of this class of restricted antibiotics for anti-infective treatment in the absence of susceptibility to the pathogen.

In conclusion, diabetes mellitus, postoperative stone residue, leukocyte count ≥ 100/HP, positive urine culture result, ureteral stent retention time ≥ 8 weeks, and high S.T.O.N.E score (especially the large stone size, severe obstruction, and multiple kidney calices involved) were independent risk factors of AP associated with ureteral stent retention after PCNL. Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis, Klebsiella pneumoniae, and Pseudomonas aeruginosa are the main pathogens of AP associated with double J-tube after PCNL. The pathogenic bacteria were sensitive to amikacin, β-lactam combined with enzyme inhibitor compound, carbapenems, and other drugs.

Author contributions GJ and ZZY designed the study. GJ and JL supervised the study. JL, HL, CQL, RJ, YYD, DXY, ZJ, and ZZY acquired and analyzed the data. All authors interpreted the data. GJ, ZZY, HL, and CQL drafted the paper. All authors critically revised the manuscript for important intellectual content.

Funding This study was supported by the Chongqing Hechuan Hongren hospital.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval This study was approved by Chongqing Hechuan Hongren hospital.

Informed consent All the patients and their families in the study signed the relevant informed consent.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Wang W, Fan J, Huang G (2017) Prevalence of kidney stones in mainland China: a systematic review. Sci Rep 7:31630
2. Ghanri KR, Andonian S, Bulititude M, Desai M, Giusti G, Okhunov Z et al (2016) Percutaneous nephrolithotomy: update, trends, and future directions. Eur Urol 70(2):382–396
3. Wu WJ, Okeke Z (2017) Current clinical scoring systems of percutaneous nephrolithotomy outcomes. Nat Rev Urol 14(8):459–469
4. Scotland KB, Lo J, Grigic T, Lange D (2019) Ureteral stent-associated infection and sepsis: pathogenesis and prevention: a review. Biofouling 35(1):117–127
5. Lange D, Binshur S, Hoag N, Chen BH (2015) Ureteral stent-associated complications—where we are and where we are going. Nat Rev Urol 12(1):17–25
6. Yoo JM, Koh JH, Han CH, Lee SL, Ha US, Kang SH (2010) Diagnosing acute pyelonephritis with CT, Tc-DMSA SPECT, and Doppler ultrasound: a comparative study. Korean J Urol 42:260–265
7. Ramakrishnan K, Scheid DC (2005) Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician 71(5):933–942
8. Johnson JR, Russo TA (2018) Acute pyelonephritis in adults. N Engl J Med 378(1):48–59
9. Inanollo SH, Yahyazadeh SR, Rashidi S, Amini E, Nowroozi MR, Ayayti M (2018) Feasibility and safety of ultrasonography guidance and flank position during percutaneous nephrolithotomy. J Urol 200(1):195–201
10. Knoll T, Daelis F, Desai J, Hoznak A, Knudsen B, Montanari E (2017) Percutaneous nephrolithotomy: technique. World J Urol 35(9):1361–1368
11. Ng FC, Yam WL, Lim TYB, Tee JK, Ng KK, Lim SK (2017) Ultrasound-guided percutaneous nephrolithotomy: advantages and limitations. Investig Clin Urol 58(5):346–352
12. Yarimoglu S, Polat S, Bozkurt IH, Yonguc T, Aydogdu O, Aydin E (2017) Comparison of S.T.O.N.E and CROES nephrolithometry scoring systems for predicting stone-free status and complication rates after percutaneous nephrolithotomy: a single center study with 262 cases. Urolithiasis 45(5):489–494
13. Yanaral F, Ozgor F, Savum M, Sahsan M, Sarilar O, Binbay M (2017) Comparison of CROES, S.T.O.N.E, and Guy’s scoring systems for the prediction of stone-free status and complication rates following percutaneous nephrolithotomy in patients with chronic kidney disease. Int Urol Nephrol 49(9):1569–1575
14. Fischer KM, Louie M, Muckavage P (2018) Ureteral stent discomfort and its management. Curr Urol Rep 19(8):64
15. Chew BH, Lange D (2016) Advances in ureteral stent development. Curr Opin Urol 26(3):277–282
16. Nouira Y, Attyaoufi K, Khaiter I, Menif E, Dahmoul H, Horchani A (2017) Percutaneous nephrolithotomy outcomes. Nat Rev Urol 14(8):459–469
17. Volchegorskii IA, Popov AN (2001) Morphometric parameters of inflammatory infiltration in renal tissue and personality characteristics of patients at risk of pyelonephritis attack after percutaneous nephrolithotomy. Bull Exp Biol Med 132(3):881–883
18. Zhu M, Wang X, Shi Z, Ding M, Fan D, Wang X (2019) Comparison between retrograde intrarenal surgery and percutaneous nephrolithitopy in the management of renal stones: a meta-analysis. Exp Ther Med 18(2):1366–1374
19. Li K, Liu C, Zhang X, Liu Y, Wang P (2013) Risk factors for septic shock after mini-percutaneous nephrolithithopy with holmium laser. Urology 81(6):1173–1176
20. Liu C, Zhang X, Liu Y, Wang P (2013) Prevention and treatment of septic shock following mini-percutaneous nephrolithotomy: a single-center retrospective study of 834 cases. World J Urol 31(6):1593–1597

 Springer
21. Rivera M, Viers B, Cockerill P, Agarwal D, Mehta R, Krambeck A (2016) Pre- and postoperative predictors of infection-related complications in patients undergoing percutaneous nephrolithotomy. J Endourol 30(9):982–986.

22. Carbone A, Al Salhi Y, Tasca A, Palleschi G, Fuschi A, De Nunzio C (2018) Obesity and kidney stone disease: a systematic review. Minerva Urol Nefrol 70(4):393–400.

23. Agaian MA, Fanardzhian SV, Muradian AA, Grabskiĭ AM (2010) Rentgenoendoscopic surgery of the complicated forms of urolithiasis with accompanying diabetes mellitus. Georgian Med News 186:19–22.

24. Tandan M, Duane S, Cormican M, Murphy AW, Vellinga A (2016) Reconsultation and antimicrobial treatment of urinary tract infection in male and female patients in general practice. Antibiotics (Basel) 15:3(3):31.

25. Linhares I, Raposo T, Rodrigues A, Almeida A (2013) Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis 13:19.

26. Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC et al (2016) Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect 22(Suppl 1):S9–S14.

27. Hu F, Guo Y, Yang Y, Zheng Y, Wu S, Jiang X et al (2019) Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis 38(12):2275–2281.

28. Lee CR, Lee JH, Park KS, Jeon JH, Kim YB, Cha CJ et al (2017) Antimicrobial resistance of hypervirulent Klebsiella pneumoniae: epidemiology, hypervirulence-associated determinants, and resistance mechanisms. Front Cell Infect Microbiol 21(7):483.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.